Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries.
paper
Cited
Public
Unavailable
- Authors
- Cogle, Christopher R; Craig, Benjamin M; Rollison, Dana E; List, Alan F
- Year
- 2011
- Journal
- Blood
- PMID
- 21531980
- DOI
- 10.1182/blood-2011-02-337964
- PMCID
- PMC3143554
The myelodysplastic syndromes (MDSs) are hematologically diverse hematopoietic stem cell malignancies primarily affecting older individuals. The incidence of MDS in the United States is estimated at 3.3 per 100 000; however, evidence suggests underreporting of MDS to centralized cancer registries. Contrary to clinical recommendations, registry guidelines from 2001-2010 required the capture of only one malignancy in the myeloid lineage and did not require blood count (BC) or bone marrow (BM) biopsy for MDS confirmation. To address these potential limitations, we constructed 4 claims-based algorithms to assess MDS incidence, applied the algorithms to the 2000-2008 Surveillance Epidemiology and End Results (SEER)-Medicare database, and assessed algorithm validity using SEER-registered MDS cases. Each algorithm required one or more MDS claims and accounted for recommended diagnostic services during the year before the first claim: 1+, 2+, 2 + BC, and 2 + BCBM (ordered by sensitivity). Each had moderate sensitivities (78.05%-92.90%) and high specificities (98.49%-99.84%), with the 2 + BCBM algorithm demonstrating the highest specificity. Based on the 2 + BCBM algorithm, the annual incidence of MDS is 75 per 100 000 persons 65 years or older-much higher than the 20 per 100 000 reported by SEER using the same sample.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Detectable clonal mosaicism from birth to old age and its relationship to cancer. | 2012 | 22561516 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Impact of thrombosis and bleeding on survival of older people with myelodysplastic syndromes: a population analysis. | Gergi M et al. | β | 2026 | β |
| Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes. | Adrianzen-Herrera DA et al. | β | 2025 | β |
| Utilization Patterns and Outcomes From Iron Chelation Therapy in Elderly Patients With Myelodysplastic Syndromes: A Population Analysis. | Strumilowska A et al. | β | 2025 | β |
| Cytogenetic profile and risk of transformation to acute myeloid leukemia (AML) in Indonesian patients with myelodysplastic syndrome (MDS): a pilot study. | Sutandyo N et al. | β | 2024 | β |
| Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies. | Molica M et al. | β | 2024 | β |
| Next generation sequencing reveals the mutation landscape of Chinese MDS patients and the association between mutations and AML transformations. | Liu Y et al. | β | 2024 | β |
| Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). | Usuki K et al. | β | 2024 | β |
| Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). | Usuki K et al. | β | 2024 | β |
| Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome. | Feng Y et al. | β | 2023 | β |
| Beyond the routine CBC: machine learning and statistical analyses identify research CBC parameter associations with myelodysplastic syndromes and specific underlying pathogenic variants. | Pozdnyakova O et al. | β | 2023 | β |
| Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies. | Gorak EJ et al. | β | 2023 | β |
| Epidemiology and Pathogenesis of Myelodysplastic Syndrome. | Rotter LK et al. | β | 2023 | β |
| Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis. | Adrianzen-Herrera D et al. | β | 2023 | β |
| Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis. | Gurule NJ et al. | β | 2023 | β |
| Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study. | Nann D et al. | β | 2023 | β |
| Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents. | Pophali P et al. | β | 2023 | β |
| A Deep Learning Model for the Automatic Recognition of Aplastic Anemia, Myelodysplastic Syndromes, and Acute Myeloid Leukemia Based on Bone Marrow Smear. | Wang M et al. | β | 2022 | β |
| Analyzing real world data of blood transfusion adverse events: Opportunities and challenges. | Jhaveri P et al. | β | 2022 | β |
| Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer. | Danese MD et al. | β | 2022 | β |
| Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis. | Sutandyo N et al. | β | 2022 | β |
| Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers. | Zhu J et al. | β | 2022 | β |
| Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis. | Adrianzen-Herrera D et al. | β | 2022 | β |
| Incidence of myeloid neoplasms in Spain (2002-2013): a population-based study of the Spanish network of cancer registries. | Solans M et al. | β | 2022 | β |
| Machine learning-based improvement of MDS-CBC score brings platelets into the limelight to optimize smear review in the hematology laboratory. | Zhu J et al. | β | 2022 | β |
| Myelodysplastic syndromes. | Li H et al. | β | 2022 | β |
| SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. | Lieu YK et al. | β | 2022 | β |
| The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication? | Cook MR et al. | β | 2022 | β |
| A machine learning approach to predicting risk of myelodysplastic syndrome. | Radhachandran A et al. | β | 2021 | β |
| Are We Undercounting MDS? An Analysis of Incidence Patterns of Myelodysplastic Syndromes in SEER 21 Regions: 2001-2016. | Shrestha A et al. | β | 2021 | β |
| Automated leukocyte parameters are useful in the assessment of myelodysplastic syndromes. | Shestakova A et al. | β | 2021 | β |
| Combination of HDE and BIIB021 efficiently inhibits cell proliferation and induces apoptosis via downregulating hTERT in myelodysplastic syndromes. | Wang B et al. | β | 2021 | β |
| Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy. | Maher M et al. | β | 2021 | β |
| Higher-risk myelodysplastic syndrome in an elderly patient: Long-term partial remission with low-dose prednisone, G-CSF, and epoetin alfa. | Islam A | β | 2021 | β |
| Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes. | Larfors G et al. | β | 2021 | β |
| Network Pharmacology and Experimental Validation Reveal the Effects of Chidamide Combined With Aspirin on Acute Myeloid Leukemia-Myelodysplastic Syndrome Cells Through PI3K/AKT Pathway. | Liang S et al. | β | 2021 | β |
| New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications. | Cristina MendonΓ§a Nogueira T et al. | β | 2021 | β |
| Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learned. | Oliva EN et al. | β | 2021 | β |
| The association between non-steroidal anti-inflammatory drugs (NSAIDs) and myelodysplastic syndromes in the Adults in Minnesota with Myelodysplastic Syndromes (AIMMS) Study. | Hubbard AK et al. | β | 2021 | β |
| The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia. | Delgado J et al. | β | 2021 | β |
| Cellular and molecular architecture of hematopoietic stem cells and progenitors in genetic models of bone marrow failure. | Heidemann S et al. | β | 2020 | β |
| GATA2 Related Conditions and Predisposition to Pediatric Myelodysplastic Syndromes. | Bruzzese A et al. | β | 2020 | β |
| Genetics of progression from MDS to secondary leukemia. | Menssen AJ et al. | β | 2020 | β |
| Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation. | Hospital MA et al. | β | 2020 | β |
| Novel combinations to improve hematopoiesis in myelodysplastic syndrome. | Syed K et al. | β | 2020 | β |
| Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. | Stanworth SJ et al. | β | 2020 | β |
| Using informatics to improve cancer surveillance. | Blumenthal W et al. | β | 2020 | β |
| Using the SEER-Medicare Data to Assess Incident Chronic Myeloid Leukemia and Bladder Cancer Cases Missed by Cancer Registries. | Lam CJK et al. | β | 2020 | β |
| Azacitidine-associated pleuropericardial effusion in myelodysplastic syndrome: A case report. | Goo K et al. | β | 2019 | β |
| Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. | Shallis RM et al. | β | 2019 | β |
| Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. | Zeidan AM et al. | β | 2019 | β |
| Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in France. | Jabagi MJ et al. | β | 2019 | β |
| Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia. | Daher-Reyes GS et al. | β | 2019 | β |
| Modeling human RNA spliceosome mutations in the mouse: not all mice were created equal. | Xu JJ et al. | β | 2019 | β |
| Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma. | Calip GS et al. | β | 2019 | β |
| Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years. | Borate U et al. | β | 2019 | β |
| Validating an algorithm for multiple myeloma based on administrative data using a SEER tumor registry and medical record review. | Brandenburg NA et al. | β | 2019 | β |
| Anemia in the Elderly. | Girelli D et al. | β | 2018 | β |
| Cohort Profile: The Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort. | Smith A et al. | β | 2018 | β |
| Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes. | Brunner AM et al. | β | 2018 | β |
| Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States. | Shenolikar R et al. | β | 2018 | β |
| Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. | Kobayashi Y et al. | β | 2018 | β |
| Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register. | Moreno Berggren D et al. | β | 2018 | β |
| Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches. | Brunner AM et al. | β | 2018 | β |
| Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States. | Ma X et al. | β | 2018 | β |
| Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group. | Drozd-SokoΕowska JE et al. | β | 2017 | β |
| Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. | Kennedy JA et al. | β | 2017 | β |
| Clinical significance of somatic mutation in unexplained blood cytopenia. | Malcovati L et al. | β | 2017 | β |
| Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes. | Drusbosky LM et al. | β | 2017 | β |
| Epoetin Ξ² pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report. | Ikenoue T et al. | β | 2017 | β |
| Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. | Ball B et al. | β | 2017 | β |
| Identifying multiple myeloma patients using data from the French health insurance databases: Validation using a cancer registry. | Palmaro A et al. | β | 2017 | β |
| Introduction. | Malcovati L | β | 2017 | β |
| Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. | Stahl M et al. | β | 2017 | β |
| Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. | Shirai CL et al. | β | 2017 | β |
| New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. | Haider M et al. | β | 2017 | β |
| PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation. | Hu C et al. | β | 2017 | β |
| Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. | Zeidan AM et al. | β | 2017 | β |
| Smoking and alcohol and subsequent risk of myelodysplastic syndromes in Japan: the Japan Public Health Centre-based Prospective Study. | Ugai T et al. | β | 2017 | β |
| The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail. | Cogle CR et al. | β | 2017 | β |
| Arsenic trioxide and triptolide synergistically induce apoptosis in the SKMβ1 human myelodysplastic syndrome cell line. | Hua HY et al. | β | 2016 | β |
| Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. | Steensma DP et al. | β | 2016 | β |
| Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy. | Cogle CR et al. | β | 2016 | β |
| Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells. | Zeng Y et al. | β | 2016 | β |
| Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia. | Garcia-Manero G et al. | β | 2016 | β |
| Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. | Garcia-Manero G et al. | β | 2016 | β |
| Emerging biological therapies for the treatment of myelodysplastic syndromes. | Zeidan AM et al. | β | 2016 | β |
| Graphical representation of clinical outcomes for patients with myelodysplastic syndromes. | Steensma DP | β | 2016 | β |
| Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. | Nazha A et al. | β | 2016 | β |
| Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes. | Abel GA et al. | β | 2016 | β |
| Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes. | Abel GA et al. | β | 2016 | β |
| Myelodysplastic Syndrome and Acute Lymphocytic Leukemia in Common Variable Immunodeficiency (CVID). | Toh J et al. | β | 2016 | β |
| Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15. | Roman E et al. | β | 2016 | β |
| Pulmonary arterial pressure in patients with myelodysplastic syndromes. | Sill H et al. | β | 2016 | β |
| Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study. | Buccisano F et al. | β | 2016 | β |
| Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study. | Khanal N et al. | β | 2016 | β |
| Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: lingering uncertainties and emerging possibilities. | Mukherjee S et al. | β | 2015 | β |
| A nationwide non-interventional epidemiological data registry on myelodysplastic syndromes in Lebanon. | Otrock ZK et al. | β | 2015 | β |
| Incidence and Burden of the Myelodysplastic Syndromes. | Cogle CR | β | 2015 | β |
| Lymphatic and hematopoietic cancers among benzene-exposed workers. | Collins JJ et al. | β | 2015 | β |
| Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment. | Zhang X et al. | β | 2015 | β |
| Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer. | Calip GS et al. | β | 2015 | β |
| Myelodysplastic syndromes in South America: a multinational study of 1080 patients. | Belli CB et al. | β | 2015 | β |
| Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. | Cogle CR et al. | β | 2015 | β |
| Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D. | Davidoff AJ et al. | β | 2015 | β |
| Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry. | Grinblatt DL et al. | β | 2015 | β |
| Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. | Wolff AC et al. | β | 2015 | β |
| Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey. | Beguin Y et al. | β | 2015 | β |
| SPAG6 silencing inhibits the growth of the malignant myeloid cell lines SKM-1 and K562 via activating p53 and caspase activation-dependent apoptosis. | Yang B et al. | β | 2015 | β |
| The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. | Dinmohamed AG et al. | β | 2015 | β |
| Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes. | Guo Y et al. | β | 2015 | β |
| Alcohol consumption and risk of myelodysplastic syndromes: A meta-analysis of epidemiological studies. | Jin J et al. | β | 2014 | β |
| Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy. | Breccia M et al. | β | 2014 | β |
| BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome cell line via the activation of caspases and inhibition of PI3K/Akt and NF-ΞΊB pathway proteins. | Lin S et al. | β | 2014 | β |
| Biology of BM failure syndromes: role of microenvironment and niches. | Balderman SR et al. | β | 2014 | β |
| Brief report: Loss of p15Ink4b accelerates development of myeloid neoplasms in Nup98-HoxD13 transgenic mice. | Humeniuk R et al. | β | 2014 | β |
| Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS). | Uno H et al. | β | 2014 | β |
| Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis. | Kunze K et al. | β | 2014 | β |
| Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. | Steensma DP et al. | β | 2014 | β |
| Established and novel agents for myelodysplastic syndromes. | Sekeres MA et al. | β | 2014 | β |
| Fishing for myelodysplastic syndromes finds uncaptured cases by state cancer registries: Need for more resources. | Cogle CR | β | 2014 | β |
| Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy. | Smith BD et al. | β | 2014 | β |
| High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. | Cogle CR et al. | β | 2014 | β |
| How we treat higher-risk myelodysplastic syndromes. | Sekeres MA et al. | β | 2014 | β |
| Incidence of myelodysplastic syndrome in Japan. | Chihara D et al. | β | 2014 | β |
| Myelodysplastic syndromes in the United States: an update for clinicians. | Troy JD et al. | β | 2014 | β |
| Radiation alone for solid tumors and the questionable development of therapy-related myelodysplastic syndromes. | Cogle CR | β | 2014 | β |
| Recent developments in myelodysplastic syndromes. | Bejar R et al. | β | 2014 | β |
| Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study. | Tatarelli C et al. | β | 2014 | β |
| Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database. | Wilson AB et al. | β | 2014 | β |
| Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). | Atallah E et al. | β | 2014 | β |
| Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. | Dinmohamed AG et al. | β | 2014 | β |
| Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study. | McQuilten ZK et al. | β | 2014 | β |
| Update on the pharmacotherapy for myelodysplastic syndromes. | Duong VH et al. | β | 2014 | β |
| 5-Azacytidine for the treatment of myelodysplastic syndromes. | Krawczyk J et al. | β | 2013 | β |
| Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. | Simonds NI et al. | β | 2013 | β |
| Flying without a net in MDS. | Sekeres MA | β | 2013 | β |
| Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes. | Castelli R et al. | β | 2013 | β |
| Methylation of promoters of microRNAs and their host genes in myelodysplastic syndromes. | Erdogan B et al. | β | 2013 | β |
| Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population-based study 1998 to 2008. | McQuilten ZK et al. | β | 2013 | β |
| [Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification]. | Schmitt-Graeff AH et al. | β | 2013 | β |
| New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice. | Tothova Z et al. | β | 2013 | β |
| Older patients/older donors: choosing wisely. | Artz AS | β | 2013 | β |
| Review of therapeutic options and the management of patients with myelodysplastic syndromes. | Γzcan MA et al. | β | 2013 | β |
| Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics. | Kern W et al. | β | 2013 | β |
| The incidence of myelodysplastic syndromes in Western Greece is increasing. | Avgerinou C et al. | β | 2013 | β |
| The role of tumor suppressor p15Ink4b in the regulation of hematopoietic progenitor cell fate. | Humeniuk R et al. | β | 2013 | β |
| Trend (1999-2009) in U.S. death rates from myelodysplastic syndromes: utility of multiple causes of death in surveillance. | Polednak AP | β | 2013 | β |
| A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. | Wang ES et al. | β | 2012 | β |
| Clonal architecture of secondary acute myeloid leukemia. | Walter MJ et al. | β | 2012 | β |
| Detectable clonal mosaicism from birth to old age and its relationship to cancer. | Laurie CC et al. | β | 2012 | β |
| Emerging immunosuppressive drugs in myelodysplastic syndromes. | Epling-Burnette PK et al. | β | 2012 | β |
| Epidemiology of myelodysplastic syndromes. | Ma X | β | 2012 | β |
| Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care. | Powers A et al. | β | 2012 | β |
| Hematologic malignancies: an opportunity to fill a gap in cancer surveillance. | Penberthy L et al. | β | 2012 | β |
| Historical perspectives on myelodysplastic syndromes. | Steensma DP | β | 2012 | β |
| MDS: unraveling the mystery. | Rizzieri DA | β | 2012 | β |
| Myelodysplastic syndromes: it is all in the genes. | Sekeres MA | β | 2012 | β |
| Myelodysplastic syndromes: the challenge of developing clinical guidelines and supportive care strategies for a rare disease. | Kurtin SE | β | 2012 | β |
| Patient and family resources for living with myelodysplastic syndromes. | Kurtin SE et al. | β | 2012 | β |
| The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. | Wang R et al. | β | 2012 | β |
| Tuning the rigging before sailing off into the stormy sea of stem cell transplants for patients with myelodysplastic syndromes. | Steensma DP | β | 2012 | β |
| What's all the fuss about? facts and figures about bone marrow failure and conditions. | Mukherjee S et al. | β | 2012 | β |
| Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes. | Craig BM et al. | β | 2011 | β |
| Implementing personalized medicine in a cancer center. | Fenstermacher DA et al. | β | 2011 | β |
| Integrating care for patients with lower risk myelodysplastic syndrome. | Garcia-Manero G | β | 2011 | β |